Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 021008

Expand all

SANDOSTATIN LAR (OCTREOTIDE ACETATE)
EQ 10MG BASE/VIAL
Marketing Status: Prescription
Active Ingredient: OCTREOTIDE ACETATE
Proprietary Name: SANDOSTATIN LAR
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: EQ 10MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N021008
Product Number: 001
Approval Date: Nov 25, 1998
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information
SANDOSTATIN LAR (OCTREOTIDE ACETATE)
EQ 20MG BASE/VIAL
Marketing Status: Prescription
Active Ingredient: OCTREOTIDE ACETATE
Proprietary Name: SANDOSTATIN LAR
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: EQ 20MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N021008
Product Number: 002
Approval Date: Nov 25, 1998
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information
SANDOSTATIN LAR (OCTREOTIDE ACETATE)
EQ 30MG BASE/VIAL
Marketing Status: Prescription
Active Ingredient: OCTREOTIDE ACETATE
Proprietary Name: SANDOSTATIN LAR
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: EQ 30MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N021008
Product Number: 003
Approval Date: Nov 25, 1998
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English